Vapendavir
Treatment of rhinovirus infection to prevent acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD)
Key Facts
About Altesa BioSciences
Altesa BioSciences is dedicated to improving the lives of people with chronic lung diseases by preemptively targeting the viral cause of acute exacerbations, rather than managing downstream consequences. Its mission centers on developing safe, effective oral medicines, starting with vapendavir for rhinovirus infections in COPD, which has shown promise in reducing symptoms, viral load, and illness duration in clinical trials. With a seasoned leadership team and plans for a pivotal Phase 2b study in 2026, Altesa is positioning itself to address a critical unmet need in respiratory medicine. The company's strategy leverages the growing availability of point-of-care diagnostics to enable timely, targeted antiviral intervention.
View full company profileAbout Altesa BioSciences
Altesa BioSciences is dedicated to improving the lives of people with chronic lung diseases by preemptively targeting the viral cause of acute exacerbations, rather than managing downstream consequences. Its mission centers on developing safe, effective oral medicines, starting with vapendavir for rhinovirus infections in COPD, which has shown promise in reducing symptoms, viral load, and illness duration in clinical trials. With a seasoned leadership team and plans for a pivotal Phase 2b study in 2026, Altesa is positioning itself to address a critical unmet need in respiratory medicine. The company's strategy leverages the growing availability of point-of-care diagnostics to enable timely, targeted antiviral intervention.
View full company profileAbout Altesa BioSciences
Altesa BioSciences is dedicated to improving the lives of people with chronic lung diseases by preemptively targeting the viral cause of acute exacerbations, rather than managing downstream consequences. Its mission centers on developing safe, effective oral medicines, starting with vapendavir for rhinovirus infections in COPD, which has shown promise in reducing symptoms, viral load, and illness duration in clinical trials. With a seasoned leadership team and plans for a pivotal Phase 2b study in 2026, Altesa is positioning itself to address a critical unmet need in respiratory medicine. The company's strategy leverages the growing availability of point-of-care diagnostics to enable timely, targeted antiviral intervention.
View full company profile